Evry, February 23, 2010 -- Généthon, the not-for-profit biotherapy research centre created by the French Muscular Dystrophy Association (AFM) and funded with donations from the country’s annual Telethon, today announced the appointment of Frédéric Revah PhD as Chief Executive.
Frédéric Revah brings over 20 years’ experience in the pharmaceutical and biotech industries and academic research to the job. Généthon will notably benefit from his acknowledged expertise in the management of therapeutic innovation. “Today, Généthon is one of the world’s benchmark labs for the development of innovative therapies for rare diseases, thanks to a unique, synergistic set of skills (ranging from research and clinical development to large-scale biomanufacturing) and exceptional support from the AFM and its donors. My goal is to pursue and accelerate this progress and deliver gene therapies to patients with rare diseases in general and neuromuscular diseases in particular”, stated Généthon’s new Chief Executive.
